Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 37Prostatic Neoplasms 12Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 3Fibrosis 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Intraductal, Noninfiltrating 3Uterine Cervical Neoplasms 2Thyroid Nodule 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma 2Lymphedema 2Leukemia, Myeloid, Acute 2Leukemia 2Inflammatory Breast Neoplasms 2Infertility 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Anatomic Stage III Breast Cancer AJCC v8 2

Interventions

Radiofrequency Ablation 2selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1Antihypertensive Agents 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenocortical Adenoma × High-Energy Shock Waves × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡